Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration by Katerina Chatzidionysiou et al.
RESEARCH ARTICLE Open Access
Effectiveness of two different doses of
rituximab for the treatment of rheumatoid
arthritis in an international cohort: data
from the CERERRA collaboration
Katerina Chatzidionysiou1*, Elisabeth Lie2, Evgeny Nasonov3, Galina Lukina3, Merete Lund Hetland4, Ulrik Tarp5,
Ioan Ancuta6, Karel Pavelka7, Dan C. Nordström8, Cem Gabay9, Helene Canhão10, Matija Tomsic11,
Piet L. C. M. van Riel12, Juan Gomez-Reino13, Tore K. Kvien2, Ronald F. van Vollenhoven1
Abstract
Background: The approved dose of rituximab (RTX) in rheumatoid arthritis is 1000 mg × 2, but some data have
suggested similar clinical efficacy with 500 mg × 2. The purpose of this study was to compare the effectiveness of
the regular and low doses given as first treatment course.
Methods: Twelve European registries participating in the CERERRA collaboration (The European Collaborative
Registries for the Evaluation of Rituximab in Rheumatoid Arthritis) submitted anonymized datasets with
demographic, efficacy and treatment data for patients who had started RTX. Treatment effectiveness was assessed
by DAS28 reductions and EULAR responses after 6 months.
Results: Data on RTX dose were available for 2,873 patients, of whom 2,625 (91.4 %) and 248 (8.6 %) received 1000
mg × 2 and 500 mg × 2, respectively. Patients treated with 500 mg × 2 were significantly older, had longer disease
duration, higher number of prior DMARDs, but lower number of prior biologics and lower baseline DAS28 than
those treated with 1000 mg × 2. Fewer patients in the low-dose group received concomitant DMARDs but more
frequently received concomitant corticosteroids.
Both doses led to significant clinical improvements at 6 months. DAS28 reductions at 6 months were comparable
in the 2 dose regimens [mean DeltaDAS28 ± SD -2.0 ± 1.3 (high dose) vs. -1.7 ± 1.4 (low dose), p = 0.23 adjusted
for baseline differences]. Similar percentages of patients achieved EULAR good response in the two dose groups,
18.4 % vs. 17.3 %, respectively (p = 0.36).
Conclusions: In this large observational cohort initial treatment with RTX at 500 mg × 2 and 1000 mg × 2 led to
comparable clinical outcomes at 6 months.
Keywords: Rituximab, Rheumatoid arthritis, Observational
* Correspondence: Aikaterini.chatzidionysiou@karolinska.se
1Department of Medicine, Karolinska Institute, Unit for Clinical Research
Therapy, Inflammatory Diseases (ClinTrid), D1:00, Karolinska
Universitetssjukhustet, 171 76, Stockholm, Sweden
Full list of author information is available at the end of the article
© 2016 Chatzidionysiou et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Chatzidionysiou et al. Arthritis Research & Therapy  (2016) 18:50 
DOI 10.1186/s13075-016-0951-z
Background
Rituximab (MabThera, Rituxan) is a chimeric, monoclo-
nal anti-CD20 antibody approved for the treatment of
rheumatoid arthritis (RA) in combination with metho-
trexate in patients with active RA who have not
responded to at least one tumor necrosis factor (TNF)
inhibitor. The efficacy and acceptable safety profile of ri-
tuximab (RTX) have been demonstrated in randomized
controlled trials [1, 2] and in large observational cohorts
[3, 4]. The approved dose is 1000 mg × 2 (with a 2-week
interval) per treatment course.
There is, however, evidence suggesting that a lower
dose of RTX, 500 mg × 2, is also effective, although not
approved. In the SERENE trial both 500 mg × 2 and
1000 mg × 2 of RTX significantly improved clinical out-
comes (based on criteria of the American College of
Rheumatology (ACR) responses, the European League
Against Rheumatism (EULAR) responses, and improve-
ment in the Disease Activity Score in 28 joints (DAS28)
and in the Health Assessment Questionnaire (HAQ))
compared to placebo in a biologic-agent-naïve popula-
tion of patients with RA [5]. The MIRROR, DANCER
and IMAGE trials yielded similar results [6–8]. In all the
above trials no significant difference was detected be-
tween the different doses in almost all clinical outcomes.
The purpose of this study was to assess and compare
the effectiveness at 6 months of the higher (1000 mg × 2)
and lower (500 mg × 2) dose of RTX given as the first
treatment course in a merged dataset from observational
cohorts.
Methods
The European Collaborative Registries for the Evaluation of
Rituximab in Rheumatoid Arthritis (CERERRA) is an
investigator-led initiative aiming to evaluate clinical aspects
of RTX use in patients with RA [4, 9]. Twelve participating
European registries (from the Czech Republic, Denmark,
Finland, The Netherlands, Norway, Portugal, Romania,
Russia, Slovenia, Spain, Sweden and Switzerland) submitted
fully anonymized datasets with baseline demographic and
disease characteristics, including age, gender, disease dur-
ation, number of previous synthetic and biological disease-
modifying anti-rheumatic drugs (DMARDs), rheumatoid
factor (RF) and anti-cyclic citrullinated peptide antibody
(anti-CCP) status of all patients with an established diagno-
sis of RA who started treatment with RTX. Data are col-
lected prospectively in each register. Ethical approval for
the use of register data from each register was obtained by
local authorities of each country. The Regional Ethical
Review Board in Stockholm approved the collection and
analysis of anonymized data from the twelve participating
registers. Informed consent was obtained from each patient
before inclusion in each register, according to local regula-
tions. Disease activity markers at baseline and after 3 and 6
months were also provided (number of swollen and tender
joints, visual analog scales (VAS) for pain, patient’s and phy-
sician’s global assessment, DAS28 and erythrocyte sedimen-
tation rate (DAS28-ESR), and HAQ). Information about
RA treatment, such as doses of RTX and use of concomi-
tant DMARDs and glucocorticoids was also included in the
dataset. Effectiveness of RTX in the higher (1000 mg × 2)
and the lower dose (500 mg × 2) was assessed by DAS28
and HAQ status at 3 and 6 months, by the improvement of
DAS28 and HAQ at 3 and 6 months, by disease activity at
3 and 6 months based on DAS28 status and by EULAR re-
sponses at 6 months. A small number of patients were
treated with other than the above doses (e.g., 750 mg) or
did not provide information on the RTX dose and were
therefore not included in the analysis.
Statistical analysis
Baseline characteristics of the two groups were analyzed
by means of descriptive statistics. For normally distrib-
uted variables mean ± standard deviation (SD) and the
independent samples t test was used, and median (inter-
quartile range (IQR)) and the Mann–Whitney U test
were used for the non-normally distributed variables.
The chi-square test was used for comparison of categor-
ical data.
Changes in DAS28 and HAQ were first compared in
unadjusted analysis using the independent samples t test.
Comparative adjusted analysis with correction for baseline
group differences was subsequently performed by analysis
of covariance (ANCOVA). In the ANCOVA we adjusted
for baseline variables found to differ significantly between
the two groups (age, disease duration, number of prior
biologic agents used, baseline DAS28, and concomitant
use of DMARDs) and for those thought to be clinically
significant (concomitant use of corticosteroids). The num-
ber of prior DMARDs used was not included in the
ANCOVA even though it was significantly different be-
tween groups, because of the small number of patients
with available information in the 500-mg group and be-
cause of the high correlation with the number of prior
biologic agents. Multivariate logistic regression analysis
was performed with EULAR response as the dependent
variable (first, analysis of good vs. moderate/no EULAR
response and second, analysis of good/moderate vs. no
EULAR response) and RTX dose (500 vs. 1000 mg), and
several baseline variables as explanatory variables (age,
gender, RA disease duration, use of previous biologic
agents, baseline DAS28, anti-CCP status, and concomitant
use of DMARDs and corticosteroids). Country was in-
cluded in the model in an additional analysis. All statistical
tests were evaluated at the 0.05 significance level. P values
and 95 % confidence intervals are presented. The statis-
tical analysis was performed with IBM SPSS Statistics
version 20.
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Results
The total number of patients included in the cohort was
3,266, and 2,873 patients (88 %) were eligible for ana-
lysis. The large majority of patients ([n = 2,625, 91.4 %)
received 1000 mg × 2 (higher dose), and 248 patients
(8.6 %) received 500 mg × 2 (lower dose). The demo-
graphics and baseline disease characteristics for the two
treatment groups are shown in Table 1. Patients who
were treated with the lower RTX dose were older, had
longer disease duration, prior use of fewer biologic
agents but more DMARDs, and lower baseline DAS28
than those treated with the higher dose. Additionally,
fewer patients in the low-dose group received concomi-
tant DMARDs but more frequently received concomi-
tant corticosteroids. Baseline characteristics for those
patients with available DAS28-ESR at 6 months are also
shown in Table 1. No significant differences between the
two populations (all patients at baseline and patients
with available response data at 6 months) were observed,
so missingness of data was not informative.
In the unadjusted analysis, the mean DAS28 im-
provement at 3 months was greater for patients
treated with the higher dose than for those treated
with the lower dose (1.9 ± 1.4 (n = 991) vs. 1.3 ± 1.3
(n = 125), p <0.0001) and it remained significant in
the ANCOVA (p = 0.004) (Table 2). The difference in
mean DAS28 improvement was also significant at 6
months (2.0 ± 1.3 (n = 1344) vs. 1.7 ± 1.4 (n = 100),
p = 0.02) in the unadjusted analysis. However, there was
no significant difference after adjustment (p = 0.23). Inclu-
sion of country as a random variable in the ANCOVA did
not change the results. Improvements in function as
assessed by the HAQ were also similar between the
groups both at 3 and 6 months (Table 2). The proportion
of patients with high, moderate and low disease activity
and remission based on the DAS28 was similar in the two
groups at baseline, 3 and 6 months (Fig. 1a), as was the
proportion of EULAR good responders, moderate re-
sponders and non-responders at 6 months (Fig. 1b).
Multivariate logistic regression analysis was performed
to examine the possible association between RTX dose
and good (vs. moderate/no) and good/moderate (vs. no)
EULAR response, with adjustment for possible con-
founders, such as age, gender, RA disease duration, pre-
vious use of biologic agents, baseline DAS28, anti-CCP
status, and use of concomitant DMARDs and corticoste-
roids. RTX dose (lower dose vs. higher dose) was not a
statistically significant predictor of achieving a good
EULAR response (odds ratio (OR) 1.08, 95 % CI 0.40,
2.94, p = 0.88) or good/moderate response EULAR (OR
1.22, 95 % CI 0.37, 4.09, p = 0.74). Similar results were
observed when country was introduced into the model.
Discussion
In this study based on data from the CERERRA collabor-
ation RTX provided significant clinical improvement at
3 and 6 months in patients with active RA. On compari-
son of the higher (1000 mg × 2) and lower dose (500 mg
Table 1 Baseline demographics, disease and treatment characteristics of patients treated with rituximab 500 mg × 2 or 1000 mg × 2 for
all patients in the cohort at baseline and for those with available response data (DAS28-ESR) at 6 months
All patients Patients with available response data at 6 months*
RTX 500 mg × 2
n = 248
RTX 1000 mg × 2
n = 2625
P value (t test,
chi-square test)
RTX 500 mg × 2
n = 109
RTX 1000 mg × 2
n = 1385
P value (t test,
chi-square test)
Sex,% female 83.9 % (248) 80.3 % (2,625) 0.17 88.1 % (109) 81.2 % (1,125) 0.08
Age, years 55.2 ± 15.8 (247) 52.6 ± 12.6 (2,615) 0.002 55.5 ± 15.1 (109) 51.1 ± 11.8 (1,380) <0.0001
Disease duration, years 10.5 (5-18) (240) 8.1 (5-14) (2,360) 0.02 10 (5-16.8) (108) 7.5 (5.1-12) (1,329) 0.02
RF, % positive 81.7 % (241) 81.2 % (2,031) 0.84 83 % (106) 81.5 % (876) 0.7
Anti-CCP, % positive 71.3 % (101) 73.4 % (806) 0.64 68 % (50) 74.9 % (363) 0.29
Number of prior biologic agents 0 (0-1) (207) 1 (0-2) (2,560) <0.0001 0 (0-1) (102) 1 (0-1) (1,371) 0.003
Anti-TNF-naive (%) 58 % (207) 37.5 % (2,560) <0.0001 58.8 % (102) 37.1 % (1,371) <0.0001
Number of prior DMARDs 2.6 ± 1.3 (126) 2.4 ± 1.4 (2,248) 0.04 2.7 ± 1.3 (55) 2.3 ± 1.1 (1,256) 0.02
Baseline DAS28-ESR 5.7 ± 1.3 (215) 6.1 ± 1.3 (2,069) <0.0001 5.9 ± 1.3 (100) 6.3 ± 1.2 (1,344) 0.002
Baseline HAQ score 1.6 ± 0.7 (212) 1.7 ± 0.7 (1,584) 0.48 1.6 ± 0.7 (100) 1.8 ± 0.7 (695) 0.001
Concomitant medication:
– Any DMARD 72.6 % (248) 83.1 % (2,625) <0.0001 75.2 % (109) 87.5 % (1,385) <0.0001
MTX 46.4 % (248) 63.4 % (2,625) <0.0001 50.5 % (109) 75.1 % (1,385) <0.0001
Glucocorticoids 65.7 % (248) 59.3 % (2,221) 0.06 71.6 % (109) 64.7 % (983) 0.15
The number of patients with available information for each variable is included in brackets. RTX rituximab, RF rheumatoid factor, anti-CCP anti-cyclic citrullinated
peptide antibodies, DMARDs disease modifying anti-rheumatic drugs, DAS28-ESR Disease Activity Score based on 28 joints and erythrocyte sedimentation rate,
HAQ health assessment questionnaire, MTX methotrexate
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× 2) of RTX there was a significant difference in DAS28
improvement at 3 months but not in clinical effective-
ness, as assessed by change in DAS28 and HAQ score at
6 months, after adjusting for baseline characteristics.
EULAR response rates and remission rates were also
similar between groups. The results of our study are
thus consistent with those from the SERENE, IMAGE
and MIRROR trials [5, 6, 8]. In the MIRROR trial the
percentage of patients with good/moderate EULAR re-
sponses was borderline significantly higher in the 1000
mg × 2 (89 %) compared to the 500 mg × 2 group (73
%) (p = 0.05). The overall conclusions of the MIRROR
trial was that the two RTX doses could not be clearly
differentiated, although some clinical outcomes were in
favor of the higher dose [6]. A recent systematic review
and meta-analysis made a similar conclusion [10]. The
similar effectiveness of lower dose RTX in patients with
RA in clinical practice might have important pharmaco-
economic implications for health systems globally.
Hitherto there have been no proper dose-response
studies for RTX in RA. What is considered the “auto-
immune dose and protocol” was developed by Professor
Jo Edwards based on a small number of patients [11].
Our study provides some additional evidence about the
lack of any striking difference and perhaps no clinically
significant difference between the two different doses of
RTX used in clinical practice. Recently interesting data
from the UK Leeds group showed that response to RTX
may be more dependent on the B-cell depletion rather
than the dose. Although in the small number of patients
studied “incomplete” peripheral blood depletion was
more often seen in the patients treated with the lower
dose, “complete” depletion was seen in both groups and
correlated better with response than dose itself [12]. The
depletion of B cells with anti-CD20 treatment varies be-
tween individuals, even with the same dose, as shown in
several animal and human studies, but tends to be con-
sistent in the same individuals [13–15]. This suggests
that individual factors are important in determining the
final extent of depletion.
There are several limitations that should be addressed:
the observational character of the study, the different
size of the two treatment groups under comparison
(only 248 patients treated with the lower dose), and the
fact that the two groups compared were not balanced
for all baseline characteristics. Hence, there is a risk of
channeling bias, as patients treated with the lower dose
were older, had longer disease duration, lower disease
activity at baseline and less prior use of biologic agents,
and were more often treated with corticosteroids and
less often with concomitant DMARDs. The lower-dose
group may represent a population of patients with more
comorbidities, for whom the treating rheumatologist
chose the lower dose of RTX. However, such a popula-
tion would be more prone to have a worse response to
therapy, and therefore confounding by indication would
bias the results against the lower dose of RTX. On asses-
sing the potential influence of corticosteroids on re-
sponse, the percentage of patients with concomitant use
of corticosteroids in the two groups was quite similar
and not statistically significant (Table 1). Additionally, in
the ANCOVA we adjusted for concomitant use of corti-
costeroids (Table 2) as it is clinically significant.
The lack of radiological data is an additional limitation
of the study. The golden triad of current treatment
guidelines in RA is remission (or low disease activity
when remission is not possible), preservation of func-
tional ability, and prevention of structural damage. Tak
et al. showed in the IMAGE study that the 1000 mg × 2
RTX, but not the 500 mg × 2 dose, significantly inhib-
ited progression of joint damage during the first 6
months, but inhibition of structural progression was
Table 2 Effectiveness of treatment across the two treatment groups as assessed by DAS28 and HAQ status and changes at 3 and 6
months
RTX 500 mg × 2 RTX 1000 mg × 2 Unadjusted p values (ANOVA) Adjusted p values**
DAS28 baseline 5.7 ± 1.3 (215) 6.1 ± 1.3 (2069) <0.0001
DAS28 3 m 4.4 ± 1.2 (138) 4.2 ± 1.3 (1046) 0.15
DAS28 6 m 4.3 ± 1.3 (109) 4.3 ± 1.2 (1385) 0.99
DeltaDAS28 3 m –1.3 ± 1.3 (125) –1.9 ± 1.4 (991) <0.0001 0.004
DeltaDAS28 6 m –1.7 ± 1.4 (100) –2.0 ± 1.3 (1344) 0.02 0.23
HAQ baseline 1.6 ± 0.7 (212) 1.6 ± 0.7 (1584) 0.48
HAQ 3 m 1.3 ± 0.7 (127) 1.3 ± 0.7 (957) 0.83
HAQ 6 m 1.2 ± 0.7 (109) 1.3 ± 0.7 (912) 0.21
DeltaHAQ 3 m –0.3 ± 0.5 (115) –0.5 ± 0.6 (859) 0.02 0.10
DeltaHAQ 6 m -0.4 ± 0.6 (103) –0.5 ± 0.7 (826) 0.13 0.27
Crude and adjusted p valued are presented. **Analysis of covariance (ANCOVA) adjusted for age, sex, disease duration, number of prior biologic agents used,
baseline Disease Activity Score in 28 joints (DAS28), concomitant use of disease-modifying anti-rheumatic drugs and glucocorticoids. RTX rituximab, HAQ Health
Assessment Questionnaire, m months
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similar from 6 months onwards [8, 16]. However, the
IMAGE trial included MTX-naïve patients of whom the
majority had early RA, and its population was thus different
from the population in our study. It would be interesting to
further evaluate the ability of the lower RTX dose to pre-
vent radiological progression in an established RA popula-
tion that is more consistent with the routine use of RTX.
The length of sustained response was not examined in the
present study. The risk that the lower dose might be associ-
ated with shorter response cannot be ruled out and should
be assessed in future studies. The large number of patients
included in the cohort, which made the comparison of the
different doses of RTX possible, and the real-life character
of the study are important strengths of the study.
Conclusions
In this large observational cohort initial treatment with
RTX at 500 mg × 2 and 1000 mg × 2 led to comparable
clinical outcomes after 6 months. This result may have
some important cost implications in the treatment of
patients with RA.
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Fig. 1 a Disease activity based on Disease Activity Score in 28 joints (DAS28)-erythrocyte sedimentation rate (ESR) at baseline, 3 and 6 months in
the two treatment groups (rituximab (RTX) 500 mg × 2 and RTX 1000 mg × 2). No significant differences were observed: remission, DAS28 <2.6;
low disease activity, 2.6≤ DAS28 ≤3.2; moderate disease activity, 3.2< DAS28 ≤5.1; high disease activity, DAS28 >5.1. b. Good, moderate or no
European League Against Rheumatism (EULAR) response at 6 months for the two treatment groups (RTX 500 mg × 2 and RTX 1000 mg × 2).
No significant differences were observed
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